Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
150.43B
Market cap150.43B
Price-Earnings ratio
20.30
Price-Earnings ratio20.30
Dividend yield
6.25%
Dividend yield6.25%
Average volume
29.54M
Average volume29.54M
High today
$26.89
High today$26.89
Low today
$26.44
Low today$26.44
Open price
$26.79
Open price$26.79
Volume
9.70M
Volume9.70M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$21.97
52 Week low$21.97

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $26.45. The company's market cap stands at 150.43B, with a P/E ratio of 20.30 and a dividend yield of 6.3%.

During the trading session on 2026-04-23, Pfizer(PFE) shares reached a daily high of $26.89 and a low of $26.44. At a current price of $26.45, the stock is +0.0% higher than the low and still -1.7% under the high.

Trading volume for Pfizer(PFE) stock has reached 9.7M, versus its average volume of 29.54M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $21.97.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $21.97.

PFE News

24/7 Wall St. 1h
Want $4,200 in Passive Income? Invest $90,000 ($30,000 Each) Into These 3 High-Yield Dividend Stocks

Want $4,200 in Passive Income? Invest $90,000 ($30,000 Each) Into These 3 High-Yield Dividend Stocks By Joel South Published Apr 23, 10:07AM EDT Quick Read AT...

Want $4,200 in Passive Income? Invest $90,000 ($30,000 Each) Into These 3 High-Yield Dividend Stocks
Nasdaq 23h
Should You Forget Pfizer and Buy This Pharma Stock Instead?

Key Points AbbVie has managed its patent-cliff concerns better. Pfizer has a higher-yielding dividend, but it may not be safe. AbbVie has the better path to...

Should You Forget Pfizer and Buy This Pharma Stock Instead?
TipRanks 1d
Notable open interest changes for April 22nd

Tuesday’s total option volume of 67.7 million contracts resulted in net open interest growth of 6.90 million calls and 7.56 million puts. NVIDIA (NVDA), Apple (...

Analyst ratings

52%

of 29 ratings
Buy
37.9%
Hold
51.7%
Sell
10.3%

More PFE News

Simply Wall St 1d
Pfizer Oncology Pivot In Focus As ASCO 2026 Data And PADCEV Loom

Pfizer (NYSE:PFE) plans to unveil major oncology pipeline updates at the ASCO 2026 Annual Meeting. The company will present new clinical data across its cancer...

Pfizer Oncology Pivot In Focus As ASCO 2026 Data And PADCEV Loom
Nasdaq 2d
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly

Key Points Novo Nordisk and Eli Lilly are largely responsible for creating today's weight-loss drug market. The two companies, however, can’t fend off creativ...

A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly
Simply Wall St 3d
Pfizer Oncology Outlook Shifts As PADCEV Keytruda Win Nears FDA Decision

Pfizer and Astellas received FDA Priority Review for PADCEV plus Keytruda as a perioperative treatment for muscle invasive bladder cancer. The application cove...

Pfizer Oncology Outlook Shifts As PADCEV Keytruda Win Nears FDA Decision
TipRanks 3d
Astellas, Pfizer announce FDA grants priority review to PADCEV, Keytruda sBLA

Astellas Pharma (ALPMY) and Pfizer (PFE) announced that the U.S. Food and Drug Administration accepted for Priority Review a supplemental Biologics License Appl...

Nasdaq 5d
Where Will Pfizer Stock Be in 3 Years?

Key Points Pfizer is facing patent cliffs on multiple drugs in the next few years. The company has been making big acquisitions to strengthen its growth prosp...

Where Will Pfizer Stock Be in 3 Years?
TipRanks 5d
Pfizer Faces Patent Cliff As New Cancer Bets Grow

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Unlock hedge fund-level data and powerful investing...

Simply Wall St 6d
Is Pfizer Offering Long Term Value After Recent Share Price Recovery

If you are wondering whether Pfizer's current share price lines up with its fundamentals, this breakdown will help you focus on what the numbers actually say ab...

Is Pfizer Offering Long Term Value After Recent Share Price Recovery

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.